Skip to main content

Advertisement

SpringerLink
Log in

Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Oncolytic viral therapy is a newly developed modality for treating tumors. Many clinical trials using oncolytic virus have been performed worldwide, but most of them have used local injection in the tumor. Determination of the effect and safety of intravascular virus injection instead of local injection is necessary for clinical use against multiple liver metastases and systemic metastases.

Methods

To evaluate the efficacy and safety of intravascular virus therapy, mice bearing multiple liver metastases were treated by intraportal or intravenous administration of the herpes simplex virus type 1 (HSV-1) mutant, hrR3. Mice treated with hrR3 were killed and organs were harvested for lacZ staining and PCR analysis. Inactivation of oncolytic virus in bloodstream was assessed by neutralization assay in vitro. Infectious activity of hrR3 with vascular endothelial cells was evaluated by replication and cytotoxicity assay.

Results

The survival rate of animals treated by hrR3 was significantly improved compared with the untreated group. lacZ staining and PCR analysis demonstrated detectable virus in the tumor but not in normal tissue or other organs except for the adrenal glands. We also showed that vascular endothelial cells allowed virus replication, while normal hepatocytes did not, and human anti-HSV antibody revealed attenuation of the infectious activity of hrR3.

Conclusions

Intravascular delivery of hrR3 is effective in treating multiple liver metastases, however, several points must be kept in mind at the time of human clinical trials using intravascular virus administration in order to avoid critical side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1064

    Article  PubMed  Google Scholar 

  2. Aita K, Irie H, Koyama AH, Fukuda A, Yoshida T, Shiga J (2001) Acute adrenal infection by HSV-1: role of apoptosis in viral replication. Arch Virol 146:2009–2020

    Article  PubMed  CAS  Google Scholar 

  3. Benencia F, Courreges MC, Conejo-Garcia JR, Bucknovich RJ, Zhang L, Carroll RH, Morgan MA, Coukos G (2005) Oncolytic HSV exerts antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 16:765–778

    Article  PubMed  CAS  Google Scholar 

  4. Biasco G, Derenzini E, Grazi GL, Ercolani G, Ravaioli M, Pantaleo MA, Brandi G (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 32:214–228

    Article  PubMed  CAS  Google Scholar 

  5. Breakefield XO, Kramm CM, Chiocca EA, Pechan PA (1996) Herpes simplex virus vectors for tumor therapy. In: Sobel RE, Scanlon KJ (eds) The internet book of gene therapy. Cancer therapeutics. Appleton & Lange, Hartford, pp 41–56

    Google Scholar 

  6. Buijs RM, Wortel J, Van Heerikhuize JJ, Feenstra MG, Ter Horst GJ, Romijn HJ, Kalsbeek A (1999) Anatomical and functional demonstration of a multisynaptic suprachiasmatic nucleus adrenal (cortex) pathway. Eur J Neurosci 5:1535–1544

    Article  Google Scholar 

  7. Burgos JS, Ramirez C, Sastre I, Bullido MJ, Valdivieso F (2002) Involvement of apolipoprotein E in the hematogenous route of herpes simplex virus type 1 to the central nervous system. J Virol 76:12394–12398

    Article  PubMed  CAS  Google Scholar 

  8. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK (1996) Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 224:323–330

    Article  PubMed  CAS  Google Scholar 

  9. Chahlavi A, Rabkin SD, Todo T, Sundaresan P, Martuza RL (1999) Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6:1751–1758

    Article  PubMed  CAS  Google Scholar 

  10. Coffey MC, Strong JE, Forsyth PA, Lee PEK (1998) Reovirus therapy of tumors with activated ras pathway. Science 282:1332–1334

    Article  PubMed  CAS  Google Scholar 

  11. Corey L, Spear PG (1986) Infection with herpes simplex viruses. N Engl J Med 314:686–691

    PubMed  CAS  Google Scholar 

  12. Delman KA, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H, Kooby DA, Hawkins WG, Horsburgh BC, Johnson P, Fong F (2000) Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 11:2465–2472

    Article  PubMed  CAS  Google Scholar 

  13. Folkman J (2003) Fundamental concepts of the angiogenic process. Curr Mol Med 3:643–651

    Article  PubMed  CAS  Google Scholar 

  14. Goldstein DJ, Weller SK (1998) Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166:41–51

    Article  Google Scholar 

  15. Hamel W, Magnelli L, Chiarugi VP, Israel MA (1996) Herpes simplex virus thimidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 56:2697–2702

    PubMed  CAS  Google Scholar 

  16. Harada Y, Kurokawa E, Endo H, Kimura T, Saito M, Sugawara Y, Irie H, Ito K, Fujii M, Shimizu Y, Kumagai K (1989) Protection of OK-432, streptococcus pyogenes preparation, against lethal infection of mice with herpes simplex virus. Microbiol Immunol 33:467–477

    PubMed  CAS  Google Scholar 

  17. Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, Breakefield XO (1998) Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumor by a HSV-1 vector. Gene Ther 5:809–819

    Article  PubMed  CAS  Google Scholar 

  18. Hill TJ, Yirrell DL, Blyth WA (1986) Infection of the adrenal gland as a route to the central nervous system after viraemia with herpes simplex virus in the mouse. J Gen Virol 67:309–320

    Article  PubMed  Google Scholar 

  19. Irie H, Harada Y, Kurokawa E, Saito M, Sugawara Y, Ohami H, Mori W (1987) Early adrenal infection by herpes simplex virus type-1 (Miyama + GC strain): special reference to inoculation dose and spread from the adrenal to the central nervous system. Virchows Arch B Cell Pathol Incl Mol Pathol 53:325–331

    Article  PubMed  CAS  Google Scholar 

  20. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer Statistics, 2007. CA Cancer J Clin 57:43–66

    Article  PubMed  Google Scholar 

  21. Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A (1999) Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 72:136–141

    Article  PubMed  CAS  Google Scholar 

  22. Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S, Kawasaki H, Choi E, Tanabe KK (2004) Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 64:2561–2567

    Article  PubMed  CAS  Google Scholar 

  23. Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F, Nishiyama Y, Nakao A (2006) Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 13:1078–1084

    Article  PubMed  Google Scholar 

  24. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 13:1325–1334

    PubMed  CAS  Google Scholar 

  25. Lorence RM, Roberts MS, O’Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK (2007) Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7:169–174

    Article  Google Scholar 

  26. MacGregor RR, Friedman HM, Macarak EJ, Kefalides NA (1980) Virus infection of endothelial cells increases granulocyte adherence. J Clin Invest 65:1469–1477

    Article  PubMed  CAS  Google Scholar 

  27. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854–856

    Article  PubMed  CAS  Google Scholar 

  28. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61:8751–8757

    PubMed  CAS  Google Scholar 

  29. Miyatake S, Yukawa H, Toda H, Matsuoka N, Takahashi R, Hashimoto N (1999) Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus. Stroke 30:2431–2439

    PubMed  CAS  Google Scholar 

  30. Modzelewski RA, Davies P, Watkins SC, Auerbach R, Chang MJ, Johnson CS (1994) Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54:336–339

    PubMed  CAS  Google Scholar 

  31. Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM, Tanabe KK (2004) Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 15:869–877

    Article  CAS  Google Scholar 

  32. Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S, Nakamura H, Donahue JM, Tanabe KK (2002) Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 236:502–513

    Article  PubMed  Google Scholar 

  33. Nachtigal M, Caulfield JB (1984) Early and late pathogenic changes in the adrenals of mice after infection with herpes simplex virus type 1. Am J Pathol 75:175–185

    Google Scholar 

  34. Nakamura H, Kasuya H, Mullen JT, Yoon SS, Pawlik TM, Chandrasekhar S, Donahue JM, Chiocca EA, Chung RY, Tanabe KK (2002) Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 109:871–882

    PubMed  CAS  Google Scholar 

  35. Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F, Nishiyama Y (2004) Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 15:987–991

    Article  Google Scholar 

  36. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, Kaye S, Kirn D (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19:289–298

    PubMed  CAS  Google Scholar 

  37. Nishiyama Y, Rapp F (1979) Regulation of persistent infection with herpes simplex virus in vitro by hydrocortisone. J Virol 31:841–844

    PubMed  CAS  Google Scholar 

  38. Oyama M, Ohigashi T, Hoshono M, Nakashima J, Tachibana M, Murai M, Uemura K, Yazaki T (2000) Intravesical and intravenous therapy of human bladder cancer by herpes vector G207. Hum Gene Ther 11:1683–1693

    Article  PubMed  CAS  Google Scholar 

  39. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA, Tanabe KK (2000) Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpes virus. Cancer Res 60:2790–2795

    PubMed  CAS  Google Scholar 

  40. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ (2002) Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62:4656–4662

    PubMed  CAS  Google Scholar 

  41. Penna C, Nordlinger B (2002) Colorectal metastasis (liver and lung). Surg Clin North Am 82:1075–1090

    Article  PubMed  Google Scholar 

  42. Potratz D, Brake B, Dienes HP, Schulz TF, Hosp M, Dierich MP, Falke D (1986) Herpes simplex virus type 1 and 2 in the adrenal glands: replication and histopathology. Arch Virol 90:207–222

    Article  PubMed  CAS  Google Scholar 

  43. Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, Nishiyama Y (2004) Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF10. J Surg Oncol 85:42–47

    Article  PubMed  CAS  Google Scholar 

  44. Visser MR, Vercellotti GM (1993) Herpes simplex virus and atherosclerosis. Eur Heart J 14:39–42

    PubMed  Google Scholar 

  45. Visser MR, Vercellotti GM, McCarthy JB, Goodman JL, Herbst TJ, Furcht LT, Jacob HS (1989) Herpes simplex virus inhibits endothelial cell attachment and migration to extracellular matrix proteins. Am J Pathol 134:223–230

    PubMed  CAS  Google Scholar 

  46. Walker JR, McGeagh KG, Sundaresan P, Jorgensen T, Rabkin SD, Martuza RL (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10:2237–2243

    Article  PubMed  CAS  Google Scholar 

  47. Wong RJ, Chan M, Yu Z, Ghossein R, Ngai I, Adusumilli PS, Stiles BM, Shah JP, Singh B, Fong Y (2004) Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10:4509–4516

    Article  PubMed  CAS  Google Scholar 

  48. Wong RJ, Chan M, Yu Z, Kim TH, Bhargava A, Stiles BM, Horsburgh BC, Shah JP, Ghossein RA, Singh B, Fong Y (2004) Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10:251–259

    Article  PubMed  CAS  Google Scholar 

  49. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK (1998) Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 228:366–374

    Article  PubMed  CAS  Google Scholar 

  50. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK (2000) An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 14:301–303

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by the Takeda Science Foundation[I] 2006.

Author information

Authors and Affiliations

  1. Department of Surgery II, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Naohiro Nomura, Hideki Kasuya, Izuru Watanabe, Toshio Shikano, Takashi Shirota, Makoto Misawa, Hiroyuki Sugimoto, Naohito Kanazumi, Shuji Nomoto, Shin Takeda & Akimasa Nakao

Authors
  1. Naohiro Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Kasuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Izuru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshio Shikano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Shirota
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Makoto Misawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Naohito Kanazumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shuji Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shin Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Akimasa Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naohiro Nomura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nomura, N., Kasuya, H., Watanabe, I. et al. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Cancer Chemother Pharmacol 63, 321–330 (2009). https://doi.org/10.1007/s00280-008-0742-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0742-6

Keywords

Search

Navigation